Pregnancy increases the risk of thrombosis. Placenta-mediated diseases are a risk factor for cardiovascular pathologies and can lead to maternal-fetal morbidity and mortality. It is essential to understand the cellular and molecular mechanisms of dysfunctions at the vascular-placental interface so that systemic vascular risk can be characterized and, ultimately, screened for, on the basis of new markers (targeted preventive management). Deregulated autophagy could be the starting point for cell death by apoptosis or necrosis leading to complications. The pathophysiological mechanisms involved in trophoblast apoptosis are incompletely described. This project follows on from the GrossAuTop-1 study, which investigated the intra- and inter-individual variability of autophagy and apoptosis activities in women during pregnancy. The aim of this project is to study autophagy and apoptosis activities specifically in women developing a placental vascular complication during pregnancy.
Age range
18 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Percentage of cells expressing LC3 (microtubule-associated protein light chain 3) protein
Timeframe: Baseline
Percentage of cells expressing LC3 (microtubule-associated protein light chain 3) protein
Timeframe: Month 1
Percentage of cells expressing LC3 (microtubule-associated protein light chain 3) protein
Timeframe: Month 2
Percentage of cells expressing LC3 (microtubule-associated protein light chain 3) protein
Timeframe: Month 3
Percentage of cells expressing LC3 (microtubule-associated protein light chain 3) protein
Timeframe: Month 4
Percentage of cells expressing LC3 (microtubule-associated protein light chain 3) protein
Timeframe: At delivery